Philips, Celsion research program moves forward

Philips Healthcare and oncology drug developer Celsion said that their joint research program has moved into the preclinical development stage.

The companies had been evaluating Celsion's ThermoDox heat-activated liposomal drug in combination with Philips' MR-guided high-intensity focused ultrasound (HIFU) technology, and will now focus on applying the combination therapy in the treatment of pancreatic cancer and cancer metastases in bone, according to Philips of Andover, MA, and Celsion of Columbia, MD.

Related Reading

Philips teams with Maquet, debuts cardiac tool, September 22, 2009

Philips launches OB ultrasound reporting package, August 27, 2009

Philips updates Xcelera for cardiology, ships CT scanner worldwide, August 19, 2009

Philips nabs Australian cardiovascular contract, August 6, 2009

Philips inks research agreement with Celsion, October 16, 2008

Copyright © 2009 AuntMinnie.com

Page 1 of 509
Next Page